Extractables & Leachables and USP <381>/<382> for Parenterals: Qualifying the Container Closure System under USP, ICH Q3E and FDA

From elastomeric component to leachable in the patient: the parenteral container closure system, qualified with the text next to every value.

USP <382> has been official since 01/12/2025 without the fragmentation section, which stays in USP <381>, and since 01/02/2026 the current text is the Revision Bulletin. ICH Q3E is a Step 2 draft of 01/08/2025, with Step 4 planned for June 2027; the August 2026 FDA draft on container closure systems is open for comment until 13/10/2026. This guide brings functional tests, extractables and leachables studies, SCT and AET thresholds, single-use and dossier together: 24 chapters in six parts, 6 appendices, 265 pages in the English edition, 267 in the Italian, and 16 editable tools, for €129.

Two separate editions: you choose the language. The guide and the toolkit exist as an English edition and as an Italian edition, with identical structure. Choose the ENG - English or the ITA - Italiano variant: the purchase gives access to the edition you choose, with its 16 tools in the same language.

One guide that replaces two. This second edition combines and replaces two guides published in first edition: “USP 382 – Implementation Guide for Parenteral Closure Systems” (December 2025) and “Extractables & Leachables (E&L) GMP – Risk-Based Operational Guide for Defensible Decisions in FDA/EMA Audits” (January 2026). It has been rewritten from scratch: container closure system and E&L now sit on a single path, with a single toolkit. If you wrote protocols or SOPs on the first editions, the front matter lists what to review first: criteria attributed to <382>, fragmentation, applicability dates, use of the TTC, status of ICH Q3E. If you bought either guide, you receive this edition at no extra cost.

A stopper that meets USP <381> does not make the system suitable. USP <382> tests how the component functions inside the system in which the drug reaches the patient: integrity, penetration, self-sealing, spike retention, plunger, tip cap. Fragmentation, which many test plans still list under <382>, was removed from the chapter before it became official: in the USA it stays in <381>, in the EU it is performed under Ph. Eur. 3.2.9.

On thresholds, three texts give different values for the same product, and none of them is binding as of 26/09/2026. The draft ICH Q3E ties the SCT to the duration of exposure: 1.5 µg/day above 10 years, 26 µg/day up to one month. PQRI 2021 uses an SCT of 1.5 µg/day and a QT of 5 µg/day; the August 2026 FDA draft gives 1.5 µg/day for most chronic-use drugs and no numerical QT. With the same extraction, the same stopper has an AET of 0.75 or 13 µg per stopper depending on the duration declared.

This guide sets every value next to the document, paragraph or line, status and market it comes from, and leaves to the company the choices that no text makes for it, each with its code, who decides and the document in which it is recorded.

This edition is written on the sources as read on 26 September 2026. Every document cited carries a status label — current, draft, in development, superseded — and, wherever a sentence could read as an obligation, a nature label: requirement, guidance, good practice, GuideGxP elaboration. The register lists 85 sources with their access date, and the 99 decisions the guide leaves to the company are tracked with who decides, on what basis and where it is recorded.

The price is €129.00. Second edition, September 2026, version 2.0, first unified edition: 265 pages in the English edition, 267 in the Italian, 24 chapters, 6 appendices and 16 editable tools.

Part I — The framework (Chapters 1–4). How to read the book, with its labels and six reading paths by role; the 1999-2027 calendar and the status of the texts; legal force by market — USA, EU, ICH and other jurisdictions; the container closure system as a system: what has to be demonstrated, and with which data.

Part II — Components and functionality (Chapters 5–10). Elastomeric components: USP <381>, <1381> and Ph. Eur. 3.2.9; USP <382>: rationale, applicability by system type and relationship with <381>; vials, bags and delivery systems; prefilled syringes, cartridges, pens and autoinjectors; container closure integrity as an interface; plastics, glass and materials: <661.1>/<661.2>, <660>, Ph. Eur. 3.1/3.2 and the EMA guideline.

Part III — Extractables and leachables (Chapters 11–16). The E&L framework: definitions, ICH Q3E, USP <1663>/<1664> and PQRI; risk assessment by dosing, route, duration, contact and materials; extractables studies, with design, conditions, supplier data and bridging; analytics and thresholds: SCT, AET, identification and quantitation; leachables studies and simulation on stability; the toxicological assessment: PDE, TTC, M7, Q3D and the classes of the draft Q3E.

Part IV — Process and single-use (Chapters 17–18). Single-use systems: USP <665>/<1665>, BPOG and Annex 1 §§8.131-8.139; suppliers, third-party data and change notification.

Part V — Dossier and lifecycle (Chapters 19–21). The dossier: CTD 3.2.P.2.4, 3.2.P.7, 3.2.S.6, DMFs and the 2026 FDA draft; change control of the container closure system and requalification; texts on the move and how to monitor them.

Part VI — Readiness and verification (Chapters 22–24). Recurring errors in eight families, each measured against a text; the gap assessment of the E&L and closure programme in fourteen areas; four case studies on Arvena Pharma — the stopper change of a lyophilisate, the prefilled syringe of an antibody, the single-use systems of the drug substance, the infusion bag — and 36 questions an inspector or assessor may ask.

Plus 6 appendices. The register of 85 sources; the status matrix by jurisdiction; the 99 decisions, each with who decides, on what basis and where it is recorded; the sheets of the 16 tools; the glossary; and Appendix F, with the AET formulas of the draft ICH Q3E transcribed character for character, a source line under each block, and the calculation examples E1–E13 that the toolkit recalculates.

Read the extract before you buy

The free extract is made of real pages from the book, not a sales summary: 20 pages in the English edition, 20 in the Italian. It contains the regulatory status box with the labels and the way USP values are read, the complete table of contents with the real page numbers, from Chapter 14 the threshold chain — the SCT, the AET formulas, the uncertainty factor and the calculation examples —, from Chapter 6 the system categories, test families and system × test matrix of <382>, Case 1 of Chapter 24 in full — the stopper change of a lyophilisate, from the supplier's change notification to the dossier — and the overview of the 16 tools.

Who it is for. QA and QPs, packaging engineering, E&L analytics, toxicologists, CMC and Regulatory Affairs, MSAT and single-use, supplier quality, consultants. It is written for whoever qualifies a container closure system, signs an extractables or leachables protocol, calculates an AET, assesses a component change or prepares Module 3 and needs to know which document every value comes from, in which version and in which market it applies.

Who it is not for. It is not a guide to container closure integrity qualification, to medical devices or to oral and inhaled dosage forms. It does not replace the official USP–NF text, which remains the reference for procedures and criteria, and it is neither legal nor toxicological advice: derived PDEs belong to a qualified toxicologist.

Describe your situation →